Provided by Tiger Trade Technology Pte. Ltd.

Contineum Therapeutics, INC.

14.82
0.0000
Post-market: 14.30-0.5200-3.51%19:30 EDT
Volume:608.39K
Turnover:9.16M
Market Cap:557.54M
PE:-8.62
High:15.51
Open:14.89
Low:14.74
Close:14.82
52wk High:17.79
52wk Low:8.60
Shares:37.62M
Float Shares:27.82M
Volume Ratio:2.14
T/O Rate:2.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7201
EPS(LYR):-2.1700
ROE:-28.01%
ROA:-19.15%
PB:2.33
PE(LYR):-6.83

Loading ...

Contineum Therapeutics CEO Carmine Stengone Disposes of Shares Worth $40,029

Reuters
·
Aug 04

Contineum Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 03

Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines

TIPRANKS
·
Aug 01

Contineum Therapeutics is Maintained at Outperform by RBC Capital

Dow Jones
·
Aug 01

RBC Lifts Price Target on Contineum Therapeutics to $23 From $22, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jul 31

Contineum Therapeutics Inc Expected to Post a Loss of 42 Cents a Share - Earnings Preview

Reuters
·
Jul 31

Contineum Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate

Benzinga Earnings
·
Jul 31

Contineum Therapeutics Inc Q2 Net Loss Per Share $0.40

THOMSON REUTERS
·
Jul 31

Contineum Therapeutics - Implements Workforce Reduction Including Chief Scientific Officer Daniel Lorrain

THOMSON REUTERS
·
Jul 31

Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth

Simply Wall St.
·
Jul 17

Contineum Therapeutics Updates Strategy, Highlights PIPE-791 Leadership

TIPRANKS
·
Jul 14

Contineum Therapeutics CSO Daniel S. Lorrain Disposes of USD 16,640 in Common Shares

Reuters
·
Jul 11

Contineum Therapeutics CEO Carmine N. Stengone Disposes of 2,500 Shares for $40,000

Reuters
·
Jul 09

Contineum Therapeutics CSO Daniel S. Lorrain Disposes of USD 556,791 Common Shares

Reuters
·
Jul 03

Contineum Therapeutics CEO Carmine Stengone Sells 10,000 Common Shares for $160,080

Reuters
·
Jul 02

Contineum publishes manuscript on PIPE-791 in Journal of Medicinal Chemistry

TIPRANKS
·
Jul 01

Contineum Launches Global Phase 2 Trial of Pipe-791 in Idiopathic Pulmonary Fibrosis Patients

Reuters
·
Jul 01

Contineum Stockholders Hold 2026 Virtual Annual Meeting

TIPRANKS
·
Jun 27

Contineum Therapeutics Shareholders Elect Class II Directors at Annual Meeting

Reuters
·
Jun 27

Contineum Therapeutics CSO Daniel S. Lorrain disposes of 4,170 common shares for $54,866.19

Reuters
·
Jun 02